US2011066251A1PendingUtilityA1

Anti-angiogenic compositions and methods of use

61
Assignee: ANGIOTECH PHARM INCPriority: Jul 19, 1993Filed: Jun 22, 2010Published: Mar 17, 2011
Est. expiryJul 19, 2013(expired)· nominal 20-yr term from priority
Inventors:William L. HunterLindsay MachanA. Arsenault
A61P 9/14A61P 9/10A61P 35/00A61P 7/02A61P 7/04A61P 43/00A61P 9/00A61P 27/02A61P 13/02A61P 11/00A61P 1/04A61P 1/16A61P 19/02A61L 31/145A61K 9/5146A61K 9/14A61K 9/1647A61K 31/185C08L 29/04A61K 33/06A61K 31/337A61K 31/427C08L 2312/00B82Y 5/00A61K 9/0019Y10S977/915A61K 31/565C07C 233/64A61L 2300/606A61K 9/1635A61L 2430/36A61K 9/5031A61K 31/519A61K 9/7007A61K 9/1641A61K 9/0051C08L 23/0853A61L 31/16A61K 33/30A61K 9/1658A61K 31/525C08L 67/04A61K 31/136A61K 31/4745A61K 31/702A61K 31/57C08L 2203/02A61K 31/203Y10S977/773A61L 2300/622A61K 33/00A61K 31/426A61K 9/5153A61K 9/0048A61K 38/57A61L 2300/416A61K 31/122A61K 31/165A61K 31/335C07K 14/811A61L 31/10A61K 45/06A61K 31/555A61K 31/20A61K 33/24
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

Claims

exact text as granted — not AI-modified
1 - 61 . (canceled) 
     
     
         62 . A method for expanding the lumen of a body passageway, comprising inserting a stent into the passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising an anti-angiogenic factor and a polymeric carrier, such that said passageway is expanded. 
     
     
         63 . The method of  claim 62 , wherein the stent is a vascular stent and the body passageway is a blood vessel. 
     
     
         64 . The method of  claim 62 , wherein the factor consists of paclitaxel. 
     
     
         65 . The method of  claim 63 , wherein the factor consists of paclitaxel. 
     
     
         66 . The method of  claim 62 , wherein the polymeric carrier is biodegradable. 
     
     
         67 . The method of  claim 62 , wherein the polymeric carrier is non-biodegradable. 
     
     
         68 . The method of  claim 62 , wherein the stent is prepared by a process comprising directly affixing the composition to the stent. 
     
     
         69 . The method of  claim 68 , wherein the stent is a vascular stent and the body passageway is a blood vessel. 
     
     
         70 . The method of  claim 68 , wherein the factor consists of paclitaxel. 
     
     
         71 . The method of  claim 62 , wherein the stent is prepared by a process comprising coating the stent with a substance and then absorbing the factor to the substance. 
     
     
         72 . The method of  claim 71 , wherein the stent is a vascular stent and the body passageway is a blood vessel. 
     
     
         73 . The method of  claim 71 , wherein the factor consists of paclitaxel. 
     
     
         74 . The method of  claim 62 , wherein the stent is inserted after angiography. 
     
     
         75 . The method of  claim 62 , wherein the body passageway is a coronary artery and the anti-angiogenic factor consists essentially of paclitaxel. 
     
     
         76 . The method of  claim 62 , wherein the body passageway is a coronary artery and the anti-angiogenic factor consists of paclitaxel. 
     
     
         77 . The method of  claim 62 , wherein the body passageway is a coronary artery and the anti-angiogenic factor comprises paclitaxel.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.